The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BAYN | +7.92% | -34.82% | -8.2% | +448% |
| S&P | +14.5% | +93.32% | +14.09% | +1,506% |
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.74B | -3.6% |
| Gross Profit | $6.38B | 3.7% |
| Gross Margin | 59.36% | 4.2% |
| Market Cap | $25.15B | -2.7% |
| Market Cap / Employee | $0.28M | 4.9% |
| Employees | 89.6K | -7.3% |
| Net Income | -$190.00M | -630.8% |
| EBITDA | $1.86B | -10.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.56B | 17.2% |
| Accounts Receivable | $12.88B | -4.2% |
| Inventory | 12.1K | -7.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $31.71B | -15.2% |
| Short Term Debt | $6.72B | -26.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -3.04% | -2.0% |
| Return On Invested Capital | -5.04% | -1.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $125.00M | -90.2% |
| Operating Free Cash Flow | $590.00M | -69.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.83 | 0.62 | 0.68 | 0.78 | 6.75% |
| Price to Sales | 0.64 | 0.41 | 0.47 | 0.54 | -1.23% |
| Price to Tangible Book Value | -1.47 | -0.96 | -1.07 | -1.38 | 9.64% |
| Price to Free Cash Flow TTM | 7.55 | 6.33 | 5.29 | 8.51 | 45.24% |
| Enterprise Value to EBITDA | 78.76 | 40.16 | 13.47 | 31.82 | -4.13% |
| Free Cash Flow Yield | 13.2% | 15.8% | 18.9% | 11.8% | -31.15% |
| Return on Equity | -2.8% | -7.9% | -9.6% | -10.3% | 196.87% |
| Total Debt | $41.16B | $40.74B | $39.39B | $38.43B | -17.50% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
